Intra-Arterial Delivery Is Not Superior to Intravenous Delivery of Autologous Bone Marrow Mononuclear Cells in Acute Ischemic Stroke | Zendy

Bing Yang | Zendy; Elton Migliati | Zendy; Kaushik Parsha | Zendy; Krystal Schaar | Zendy; Xiaopei Xi | Zendy; Jaroslaw Aronowski | Zendy; Sean I. Savitz | Zendy

Open Access

Intra-Arterial Delivery Is Not Superior to Intravenous Delivery of Autologous Bone Marrow Mononuclear Cells in Acute Ischemic Stroke

Author(s) -

Bing Yang,

Elton Migliati,

Kaushik Parsha,

Krystal Schaar,

Xiaopei Xi,

Jaroslaw Aronowski,

Sean I. Savitz

Publication year - 2013

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.000821

Subject(s) - medicine , bone marrow , saline , stroke (engine) , proinflammatory cytokine , peripheral blood mononuclear cell , spleen , microglia , anesthesia , inflammation , mechanical engineering , chemistry , biochemistry , engineering , in vitro

Bone marrow-derived mononuclear cells (MNCs) are an investigational autologous cell-based therapy for acute ischemic stroke. Both intravenous (IV) and intra-arterial (IA) administration routes have been used in clinical trials. However, the route of administration to optimize the effect of MNCs is unknown. In this study, we compared the effect of IV versus IA route of administration of MNCs in the rat stroke model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research